New Calculator Exposes 340B Program's Hidden Costs to Employers

WASHINGTON, DC – April 02, 2026 – A major coalition representing American businesses has launched a first-of-its-kind tool designed to pull back the curtain on the hidden costs employers face from a sprawling federal drug discount program. The National Alliance of Healthcare Purchaser Coalitions today released its 340B Employer Cost Impact Calculator, a digital tool that aims to quantify how a program intended to support safety-net hospitals is allegedly driving up health plan spending for millions of workers and their families.

This move escalates a long-simmering debate over the 340B Drug Pricing Program, pitting hospitals that benefit from it against employers and pharmaceutical manufacturers who claim it has strayed far from its original mission. The new calculator enables companies to estimate their own financial burden from the program's complex dynamics, providing ammunition for those seeking greater transparency and reform.

"The 340B program plays an important role in our healthcare system, but its unintended consequences have gone unchecked for far too long," said Shawn Gremminger, president and CEO of the National Alliance. "Employers deserve transparency about how the hidden costs of the program affect their health plans and their people. This calculator gives purchasers the clarity they need to understand the impact and drive more informed, value based decisions."

A Safety Net with Unintended Holes

Established in 1992, the 340B program was created to help vulnerable patients by allowing certain safety-net providers, known as "covered entities," to purchase outpatient drugs from manufacturers at a steep discount. The core concept was to allow these providers—such as community health centers and hospitals serving a high proportion of low-income patients—to "stretch scarce federal resources."

The mechanism is straightforward: an eligible hospital buys a drug at the discounted 340B price but receives reimbursement from insurers, including employer-sponsored plans, at a much higher, standard rate. The hospital then keeps the difference, or "spread." The intent was for this revenue to subsidize patient care, offset uncompensated care, and support community health initiatives.

However, the program has grown exponentially, from a niche program to the second-largest federal drug program behind Medicare Part D, with annual drug purchases exceeding $81 billion. Critics argue this explosive growth, fueled by legislative expansions and the proliferation of "contract pharmacies," has distorted the program's purpose. Instead of solely benefiting the uninsured and underinsured, they contend it has become a significant revenue generator for hospitals, with little transparency or accountability for how the savings are used.

The Hidden Tax on Employers

For employers, who provide health coverage for over 90 million Americans, the program's impact is felt not in discounts but in rising costs. The National Alliance and other critics point to several ways the 340B program inflates commercial health plan spending.

One of the primary drivers is the loss of manufacturer rebates. Employer plans typically rely on rebates negotiated by their Pharmacy Benefit Managers (PBMs) to lower the net cost of prescription drugs. However, drugs purchased under 340B discounts are generally ineligible for these commercial rebates. When a hospital dispenses a 340B-acquired drug to an employee on a company health plan, the plan pays the full price without receiving the rebate it otherwise would have, effectively increasing the net cost. Studies by research firms like IQVIA have sought to quantify these "lost savings" for commercial plans, suggesting they are substantial.

Furthermore, the program's structure can create perverse incentives. Because the profit margin for a 340B entity is the difference between the discounted purchase price and the insurer's reimbursement, there is a financial incentive to prescribe more expensive drugs that have a larger spread. This can lead to shifts in care to more expensive hospital-owned outpatient facilities and discourage the use of lower-cost biosimilars, ultimately driving up overall plan costs without any direct benefit to the employee receiving the medication.

A Widening Chasm of Stakeholders

The debate over 340B has created a deep divide among healthcare stakeholders. On one side, hospital groups like the American Hospital Association (AHA) vigorously defend the program, arguing it is a financial lifeline that enables them to care for vulnerable communities. They assert that 340B savings are essential for offsetting government underpayment and the high cost of uncompensated care, and that any cuts to the program would directly harm patient services.

On the other side, pharmaceutical manufacturers, represented by groups like PhRMA, argue the program is rife with abuse and lacks oversight. They contend that the benefits are often captured by hospitals and contract pharmacies as profit rather than being passed on to patients. This has led some manufacturers to restrict 340B discounts at contract pharmacies, sparking a series of high-stakes legal battles with the federal government.

Caught in the middle are employers and the PBMs that manage their drug benefits. Employer groups argue they are being forced to unknowingly subsidize hospital profits through higher premiums and costs, a sentiment echoed in the launch of the new calculator. PBMs navigate a complex role, sometimes developing tools to help employers identify 340B claims while also managing the transactions that are central to the program's function.

Data as a New Weapon for Transparency

The 340B Employer Cost Impact Calculator represents a new strategy in this conflict: empowering individual employers with data. The tool uses a model built on publicly available information, including the government's own database of 340B-registered facilities (HRSA OPAIS), US Census data, and state-level rebate loss estimates from independent research.

By inputting company-specific information, an employer can receive an estimate of the additional cost per covered employee and the total annual financial burden attributable to the 340B program's market effects. The National Alliance encourages its members to use these estimates to initiate pointed conversations with their PBMs and to advocate for policy changes at both state and federal levels.

This push for data-driven transparency comes as the 340B program faces intense scrutiny in Washington. Congressional committees have held numerous hearings examining the program's integrity, and various legislative proposals have been introduced to reform its structure, enhance reporting requirements, and more clearly define which patients are eligible. The ongoing legal fights between drug makers and the government over contract pharmacies further highlight the instability and contention surrounding the program, ensuring that the battle over its future, and its costs, is far from over.